IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Farina, Mirko
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.926
AS - Asia 2.300
EU - Europa 1.775
SA - Sud America 517
AF - Africa 67
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.601
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.824
SG - Singapore 998
IT - Italia 567
CN - Cina 514
BR - Brasile 445
DE - Germania 293
HK - Hong Kong 291
FI - Finlandia 165
VN - Vietnam 146
GB - Regno Unito 117
UA - Ucraina 115
RU - Federazione Russa 107
FR - Francia 94
TR - Turchia 91
IN - India 61
CA - Canada 52
PL - Polonia 48
IE - Irlanda 47
SE - Svezia 41
BD - Bangladesh 40
CZ - Repubblica Ceca 38
ZA - Sudafrica 36
MX - Messico 32
NL - Olanda 31
AT - Austria 30
JP - Giappone 30
AR - Argentina 25
IQ - Iraq 22
ES - Italia 21
BE - Belgio 18
ID - Indonesia 15
AU - Australia 14
EC - Ecuador 12
EG - Egitto 10
SA - Arabia Saudita 9
TH - Thailandia 9
CO - Colombia 8
KR - Corea 8
IL - Israele 7
LT - Lituania 7
UZ - Uzbekistan 7
MA - Marocco 6
OM - Oman 6
PE - Perù 6
PY - Paraguay 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
GR - Grecia 5
PA - Panama 5
PS - Palestinian Territory 5
PT - Portogallo 5
TW - Taiwan 5
KE - Kenya 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LK - Sri Lanka 4
LV - Lettonia 4
MY - Malesia 4
UY - Uruguay 4
CH - Svizzera 3
CL - Cile 3
ET - Etiopia 3
IR - Iran 3
JM - Giamaica 3
JO - Giordania 3
SK - Slovacchia (Repubblica Slovacca) 3
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
HU - Ungheria 2
LB - Libano 2
NO - Norvegia 2
NP - Nepal 2
PH - Filippine 2
RO - Romania 2
TN - Tunisia 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
CI - Costa d'Avorio 1
GH - Ghana 1
IM - Isola di Man 1
MD - Moldavia 1
MS - Montserrat 1
MT - Malta 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
SN - Senegal 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.601
Salva come PNG Salva come JPEG
Città #
Singapore 422
Ashburn 332
Hong Kong 289
Fairfield 180
New York 164
Munich 161
Beijing 152
Dallas 128
Los Angeles 120
Chandler 118
Brescia 108
Helsinki 98
Woodbridge 91
Seattle 82
Wilmington 80
Jacksonville 77
Des Moines 73
Houston 70
Princeton 68
Istanbul 65
The Dalles 63
Milan 55
Ho Chi Minh City 51
Turku 50
Boardman 49
São Paulo 49
Cambridge 47
Shanghai 46
Redondo Beach 44
Dublin 43
San Francisco 43
Moscow 40
Chicago 39
Hanoi 35
Warsaw 35
Buffalo 33
Ann Arbor 32
Santa Clara 32
London 28
Brno 26
Tokyo 26
Frankfurt am Main 24
Rome 24
Brooklyn 22
Denver 22
Johannesburg 22
Nuremberg 20
Romola 19
Stockholm 18
Montreal 16
Orem 16
Toronto 16
Phoenix 15
Poplar 15
Boston 14
Mexico City 14
Pune 14
Atlanta 13
Lappeenranta 13
Nanchang 13
Nanjing 13
San Diego 13
Wroclaw 13
Barlassina 12
Charlotte 12
Vienna 12
Brussels 11
Manchester 11
Tianjin 11
Verona 11
Brasília 10
Rio de Janeiro 10
Belo Horizonte 9
Chennai 9
Dearborn 9
Düsseldorf 9
Florence 9
Jinan 9
Olomouc 9
Biên Hòa 8
Curitiba 8
Amsterdam 7
Bergamo 7
Bologna 7
Bosio 7
Da Nang 7
Genoa 7
Lauterbourg 7
Philadelphia 7
Porto Alegre 7
Salvador 7
Tashkent 7
Turin 7
Baghdad 6
Changsha 6
Melbourne 6
Paris 6
Portsmouth 6
Salt Lake City 6
Shenyang 6
Totale 4.418
Salva come PNG Salva come JPEG
Nome #
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors and Circulating Endothelial Cells in Patients With Primary Myelofibrosis 189
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 183
Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma 151
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 151
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 148
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 142
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 140
Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia 139
Advances in CMV Management: A Single Center Real-Life Experience 138
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 134
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 134
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 129
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 127
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 121
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 118
Identification of Relapse Risk Using a Multiparameter Flow Cytometry-Based Detection of Minimal Residual Disease in Adult Patients with Acute Myeloid Leukemia at ELN Intermediate-Risk 109
Comparative monitoring of deep molecular response (DMR) by RT-quantitative (RT-qPCR) and digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) patients treated with TKIs for recognition of stable deep molecular response (DMR) and identification of best candidates to TKIs treatment discontinuation. 109
OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 108
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 108
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 105
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey) 105
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 104
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 104
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 103
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 98
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent 93
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol) 93
Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection 92
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA 91
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis 90
POST REMISSION SEQUENTIAL MONITORING OF MINIMAL RESIDUAL DISEASE BY WT1 Q-PCR AND MULTIPARAMETRIC FLOW CYTOMETRY PREDICTS RELAPSE AND MAY HELP TO ADDRESS THE RISK ADAPTED THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS 89
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients 87
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2) 86
Nutritional intervention with TGF-beta enriched food for special medical purposes (TGF-FSMP) is associated with a reduction of malnutrition, acute GVHD, pneumonia and may improve overall survival in patients undergoing allogeneic hematopoietic stem transplantation 85
Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients 83
Pre-Emptive Donor Lymphocyte Infusion As Optimal Treatment for Relapsed Acute Myeloid Leukemias and Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation: Insights from a French-Italian Study on 134 Patients 82
dsDNA from extracellular vesicles (EVs) in adult AML 82
3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients 81
Is the New Tci Score Sufficient to Categorize the Intensity of Conditioning? a Single-Centre Study 80
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors 80
PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY 80
How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation 78
Potentiality of Bone Marrow-Derived Mesenchymal Stromal Cells (BM-MSCs) to Differentiate into the Osteogenic Lineage in in Vitro Model of Tissue Regeneration 77
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation 76
Evaluation of Circulating Endothelial Cells (CECs) As Marker of Endothelial Damage in Allo-Transplanted Patients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): The Cecinvod Study 75
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome 74
Nutritional strategies to improve VRE control 74
Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report 73
PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS 72
Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients 71
Neuro-toxoplasmosis in haploidentical haematopoietic stem cell transplant 71
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 69
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 69
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study 67
Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study 66
Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS‐Relapse Registry Study 66
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia 66
Immune Reconstitution after Allogenic Stem Cell Transplantation in Patients with Myelofibrosis 66
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 65
S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 63
Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation (Bone Marrow Transplantation, (2023), 10.1038/s41409-023-02124-y) 63
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan 62
Exosomes and Extracellular Vesicles in Myeloid Neoplasia: The Multiple and Complex Roles Played by These “Magic Bullets” 62
Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French–Italian Experience of 134 Patients 61
In Vitro Biocompatibility Assessment of Bioengineered PLA-Hydrogel Core–Shell Scaffolds with Mesenchymal Stromal Cells for Bone Regeneration 61
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study 61
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 61
Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey) 60
MALNUTRITION AND GVHD IN ALLOGENIC BONE MARROW TRANSPLANTATION: A PROSPECTIVE STUDY 57
CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB 57
PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY 57
Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors 54
Digital PCR as a New Method for Minimal Residual Disease Monitoring and Treatment Free Remission Management in Chronic Myeloid Leukemia Patients: Is It Reliable? 53
Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients 52
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis 52
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 51
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms 51
Isolated Cerebral Myeloid Sarcoma in an Allogeneic Stem Cell Transplant Recipient 49
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study 47
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study 46
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 45
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study 43
S157: BCR::ABL1 DIGITAL PCR IDENTIFIES CHRONIC PHASE CML PATIENTS SUITABLE FOR AN EARLY TKI DISCONTINUATION ATTEMPT: A PATIENT-LEVEL META-ANALYSIS 42
The possible role of mutated endothelial cells in myeloproliferative neoplasms 42
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION 41
Intensive Chemotherapy Versus Venetoclax-Based Regimens in Elderly Patients with Acute Myeloid Leukemia: Is the Chemotherapy Era Ending? 41
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION 41
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis 41
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib 39
Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient 37
Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study 35
Impact of transforming growth factor-β2 enriched food for special medical purposes on nutritional status, microbiota and clinical outcomes after allogeneic hematopoietic stem cell transplantation: prospective analysis of 192 consecutive patients 34
Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor? 33
Successful CAR-T cell therapy in a refractory mcl patient with rapidly progressive disease: a case report 33
Do Unexpected and Cryptic FISH Lesions Of Chromosomally Normal MDS Patients Have Any Prognostic Relevance? 32
A case of Severe Gastrointestinal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation: Can We Improve the Evaluation of the “Gut Fitness”? 28
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 25
Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50 25
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis 20
Assessment of Chronic Myeloid Leukaemia In Vitro Models Variability: Insights Into Extracellular Vesicles 19
Totale 7.722
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.229
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.229
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021341 0 0 0 0 0 63 29 53 47 84 34 31
2021/2022354 22 15 11 44 13 18 19 39 22 48 22 81
2022/2023445 45 12 17 41 33 88 2 53 55 11 36 52
2023/2024808 31 21 57 52 59 154 43 45 133 27 24 162
2024/20252.506 27 60 57 246 178 181 175 123 400 238 478 343
2025/20262.728 405 549 395 734 587 58 0 0 0 0 0 0
Totale 7.740